News

At MacuSight, Mr Wroblewski will be responsible for overseeing functions related to each of these areas of expertise to support the company’s broad Phase II clinical development program

The double-blind, vehicle-controlled study is designed to evaluate the tolerability and efficacy of the topical product in a total of 18 subjects with mild to moderate forms of

Dr Fibiger, a fellow of the American College of Neuropsychopharmacology, was most recently chief scientific officer of MedGenesis Therapeutix, a privately held biopharmaceutical company based in Victoria, British

In addition to pursuing its new pipeline expansion strategy, the company said that it will continue with its plans to develop AKP-020 for Type 2 diabetes. Having completed

On a GAAP basis, net income for the third quarter of 2008 was $44.7 million, or $0.63 per diluted share, compared to $42.8 million, or $0.62 per diluted

Within the next few days the safety report of this study will be submitted to the FDA and this will trigger a $25 million milestone payment under the

Salvat expects the FDA to classify the complete response as a class 2 resubmission, under which the FDA will seek to complete its review of the resubmission within

The collaboration, originally established in January of 2006 for a period of two years, was extended in 2007, at Bristol-Myers Squibb’s request, through January 12, 2009. Bristol-Myers Squibb

The application processes to the national regulatory agencies and ethics committees have proceeded according to plan, and the company has now received agency approvals for a European Phase